zegocractin: Clinical Trials

6 trials of zegocractin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 recruiting, 1 withdrawn. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Terminated 2, Recruiting 1, Withdrawn 1
Phase 11Recruiting 1

Follow zegocractin: new trials by email Literature Review of zegocractin trials Research Report on zegocractin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Auxora, Placebo - Acute Kidney Injury
Phase 2TerminatedCalciMedica, Inc.1222024-07-012026-08-31
A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia
Auxora, Placebo - Pneumonia
Phase 2WithdrawnCalciMedica, Inc.2022-01-242022-03-31
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
CM-4620 Injectable Emulsion or CM-4620-IE, Placebo - Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Phase 2CompletedCalciMedica, Inc.2162021-03-242026-08-24
A Study of Auxora in Patients With Critical COVID-19 Pneumonia
CM4620-IE (Injectable Emulsion), Placebo - Pneumonia
Phase 2TerminatedCalciMedica, Inc.102021-03-022026-09-09
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
CM4620 - Acute Pancreatitis
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital422020-09-042026-06-03
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2) - Pneumonia
Phase 2CompletedCalciMedica, Inc.3142020-04-082026-03-30

Conditions studied

COVID-19 (3)  ·  Coronavirus Infections (3)  ·  Pneumonia (3)  ·  Pancreatitis (2)  ·  Acute Kidney Injury (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Systemic Inflammatory Response Syndrome (1)

Sponsors

CalciMedica, Inc. (5)  ·  St. Jude Children's Research Hospital (1)

Countries

United States (6)  ·  India (1)

Top investigators

Sudarshan Hebbar, MD (3)  ·  Seth E. Karol, MD (1)  ·  Sudarshan Hebbar, MD, Chief Medical Officer (1)

Results publications

PMID 32795330, PMID 35395943, PMID 41938843, PMID 42518274